tetano
Editor, Senior Moderator
Emerg Infect Dis
. 2021 Feb 4;27(4).
doi: 10.3201/eid2704.204895. Online ahead of print.
COVID-19-Associated Pulmonary Aspergillosis, March-August 2020
Jon Salmanton-Garc?a, Rosanne Sprute, Jannik Stemler, Michele Bartoletti, Damien Dupont, Maricela Valerio, Carolina Garc?a-Vidal, Iker Falces-Romero, Marina Machado, Sof?a de la Villa, Maria Schroeder, Irma Hoyo, Frank Hanses, Kennio Ferreira-Paim, Daniele Roberto Giacobbe, Jacques F Meis, Jean-Pierre Gangneux, Azucena Rodr?guez-Guardado, Spinello Antinori, Ertan Sal, Xhorxha Malaj, Danila Seidel, Oliver A Cornely, Philipp Koehler, FungiScope European Confederation of Medical Mycology/The International Society for Human and Animal Mycology Working Group2
Abstract
Pneumonia caused by severe acute respiratory syndrome coronavirus 2 emerged in China at the end of 2019. Because of the severe immunomodulation and lymphocyte depletion caused by this virus and the subsequent administration of drugs directed at the immune system, we anticipated that patients might experience fungal superinfection. We collected data from 186 patients who had coronavirus disease-associated pulmonary aspergillosis (CAPA) worldwide during March-August 2020. Overall, 182 patients were admitted to the intensive care unit (ICU), including 180 with acute respiratory distress syndrome and 175 who received mechanical ventilation. CAPA was diagnosed a median of 10 days after coronavirus disease diagnosis. Aspergillus fumigatus was identified in 80.3% of patient cultures, 4 of which were azole-resistant. Most (52.7%) patients received voriconazole. In total, 52.2% of patients died; of the deaths, 33.0% were attributed to CAPA. We found that the cumulative incidence of CAPA in the ICU ranged from 1.0% to 39.1%.
Keywords: Aspergillus; COVID-19; SARS-CoV-2; aspergillosis; coronavirus disease; coronaviruses; fungi; intensive care unit; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; voriconazole; zoonoses.
. 2021 Feb 4;27(4).
doi: 10.3201/eid2704.204895. Online ahead of print.
COVID-19-Associated Pulmonary Aspergillosis, March-August 2020
Jon Salmanton-Garc?a, Rosanne Sprute, Jannik Stemler, Michele Bartoletti, Damien Dupont, Maricela Valerio, Carolina Garc?a-Vidal, Iker Falces-Romero, Marina Machado, Sof?a de la Villa, Maria Schroeder, Irma Hoyo, Frank Hanses, Kennio Ferreira-Paim, Daniele Roberto Giacobbe, Jacques F Meis, Jean-Pierre Gangneux, Azucena Rodr?guez-Guardado, Spinello Antinori, Ertan Sal, Xhorxha Malaj, Danila Seidel, Oliver A Cornely, Philipp Koehler, FungiScope European Confederation of Medical Mycology/The International Society for Human and Animal Mycology Working Group2
- PMID: 33539721
- DOI: 10.3201/eid2704.204895
Abstract
Pneumonia caused by severe acute respiratory syndrome coronavirus 2 emerged in China at the end of 2019. Because of the severe immunomodulation and lymphocyte depletion caused by this virus and the subsequent administration of drugs directed at the immune system, we anticipated that patients might experience fungal superinfection. We collected data from 186 patients who had coronavirus disease-associated pulmonary aspergillosis (CAPA) worldwide during March-August 2020. Overall, 182 patients were admitted to the intensive care unit (ICU), including 180 with acute respiratory distress syndrome and 175 who received mechanical ventilation. CAPA was diagnosed a median of 10 days after coronavirus disease diagnosis. Aspergillus fumigatus was identified in 80.3% of patient cultures, 4 of which were azole-resistant. Most (52.7%) patients received voriconazole. In total, 52.2% of patients died; of the deaths, 33.0% were attributed to CAPA. We found that the cumulative incidence of CAPA in the ICU ranged from 1.0% to 39.1%.
Keywords: Aspergillus; COVID-19; SARS-CoV-2; aspergillosis; coronavirus disease; coronaviruses; fungi; intensive care unit; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; voriconazole; zoonoses.